Postpartum Dönemde Başvuran Hastalara Uygulanan Servikal Sitoloji (Pap Smear) ve/veya Hpv Test Sonuçlarının Analizi
View/ Open
Date
2022-09-13Author
ALPAN, Dilara
xmlui.dri2xhtml.METS-1.0.item-emb
Acik erisimxmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
ABSTRACT
Alpan D., The Analysis of the Results of Cervical Cytology (Pap Smear) Tests
and/or HPV Test Applied to the Patients Admitted in the Postpartum Period,
Hacettepe University Faculty of Medicine, Obstetrics and Gynecology
Dissertation Thesis, Ankara 2022
Cervical cancer is the fourth most prevalent type of cancer among females. It
ranks second in female cancer mortalities. Cervical cancer is the most diagnosed
malignity in pregnancy, with an incidence of 0.8-1.5 cases per 10,000 deliveries.
Cervical cancer and premalignant lesion screening programs are applied with cervical
cytology (PAP smear) and/or HPV tests, which are an essential part of both our
country's health policies and preventive health services in the world. The positive
cytology (PAP Smear) ratio in a non-pregnant population is approximately 3% in
general, but it can range between 1% and 9.7%. According to the literature, the
prevalence of cervical intraepithelial neoplasia (CIN) in pregnant women is
approximately 1%, and these results are similar to those of the non-pregnant
population. The hormonal environment, which changes during pregnancy, (steroid
increase) and immune response during pregnancy can support the presence or
persistence of HPV infection. A systematic review of the literature revealed that the
prevalence of HPV in pregnant women ranges from 5.5% to 65%. In a recent study on
pregnant and non-pregnant women of the same age, Luo et al. discovered that while
the HPV prevalence in non-pregnant women was 14.8%, it was higher in pregnant
women at 24.2%. Premature ruptures of the membrane (PROM) of several HPVs were
found to be associated with preeclampsia, fetal growth restriction, preterm delivery,
and placental abnormalities in several populations. The cumulative evidence suggests
that the possibility of HPV infection continuing during pregnancy and postnatal
regression is high. Cervical cancer screening as an antepartum routine is not performed
at our center. Cervical cancer screening is used for women who should have a smear
or an HPV test when they come for a check-up in the postpartum sixth week.
Therefore, the smear and HPV results of patients who came in for a postpartum checkup were examined retrospectively in our study. The number of patients who underwent
the HPV test (n = 73) was lower than the number of patients who underwent the smear
test. This situation is believed to be the result of the ASCCP/ ACS/ ASCP/ WHO/
Republic of Türkiye Ministry of Health's recommendations for the HPV test to be
administered to individuals aged 30 or above. The mean age in our study was 29.5,
supporting this argument. Examining the test results of the 1012 patients in the
postpartum period who had smear tests, 98.1% of were negative, 0.6% were (n=6)
ASCUS, and 0.4% were LSIL (n=4). When the HPV results were examined, it was
found that 6.4% were negative and 0.8% (n=8) were positive. The following HPV
types were found in the patients who tested positive for HPV: HPV type 16 in two
patients, HPV type 53 in three patients, HPV type 54 in one patient, HPV type 59 in
one patient, and HPV type 66 in one patient. Out of 1003 patients, %99 tested negative
for smear, while 1% tested positive. Out of 73 patients, %89 tested negative for HPV,
while 11% tested positive. When the results of our study were reviewed, no patients
with HSIL cytology or cervical cancer were found. There are studies in the literature
indicating that people with positive HPV tests and/or smear test results are more likely
to experience adverse obstetric outcomes. However, in the present study, no
relationship was found between infants' birth weight, live birth or stillbirth, the need
for advanced life support during delivery, preterm labor, IUGR and macrosomic fetus
rates, and the mothers' smear or HPV results. While the APGAR scores did not change
according to the smear results, the APGAR3 score was found to be significantly higher
in the HPV-negative patients compared to those who are HPV positive. This study,
which identified no significant association between drug utilization features and HPV
and/or smear results, and studies indicating that the incidence of permanent hrHPV
infection increases in individuals with immunosuppression and/or using
immunosuppressive drugs are inconsistent. No relationship was detected between the
mother's internal diseases, immunosuppression status, and smear results. When HPV
results were examined, neurologic diseases were found to be more common in HPVpositive patients. There is no difference in other diseases or immunosuppressive status
based on HPV results. Studies comparing HPV and/or smear tests performed during
both the antepartum and postpartum periods within the parameters of this study will
advance the research.
Keywords: Cervical Cancer, Cervical Cancer Screening, Colposcopy, HPV, Pap
Smear, Postpartum Period, Pregnancy